Education
About Us
Working with TipRanks
Follow Us
BioLargo (BLGO)
OTHER OTC:BLGO
Top Page
BioLargo
(OTC:BLGO)
48Neutral
BioLargo (BLGO) vs. S&P 500 (SPY)
Market Cap
$64.17M
Dividend YieldN/A
Average Volume (3M)274.19K
Price to Earnings (P/E)―
Beta (1Y)-0.34
Revenue Growth22.97%
EPS Growth17.32%
CountryUS
Employees40
SectorBasic Materials
Sector Strength60
IndustryChemicals
Share Statistics
EPS (TTM)N/A
Shares Outstanding302,840,760
10 Day Avg. Volume462,777
30 Day Avg. Volume274,192
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)8.31
Price to Sales (P/S)0.00
P/FCF Ratio-10.76
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit8.77
Enterprise Value/Ebitda-3.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioLargo Business Overview & Revenue Model
Company DescriptionBioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
How the Company Makes MoneyBioLargo makes money through the sale and licensing of its proprietary technologies and products. Key revenue streams include direct sales of their water treatment systems and odor control products to industrial and municipal clients, as well as licensing agreements for the use of their patented technologies. The company also generates income through strategic partnerships with other organizations that leverage BioLargo's innovations to enhance their own product offerings. Additionally, consulting services provided by BioLargo Engineering, Science & Technologies (BLEST) contribute to the company's revenue by offering specialized expertise in environmental engineering projects.
BioLargo Financial Statement Overview
Summary
BioLargo exhibits strong revenue growth from $1.86M in 2019 to $17.78M in 2024, but faces challenges with profitability and cash flow. Net losses persist with a $2.40M loss in 2024 and operational cash flow remains negative, indicating financial management challenges.Income Statement
BioLargo has demonstrated significant revenue growth, increasing from $1.86M in 2019 to $17.78M in 2024, showing a strong upward trajectory. However, the company remains unprofitable with consistent net losses, including a net loss of $2.40M in 2024. The gross profit margin has improved but remains volatile. EBIT and EBITDA margins remain negative, indicating operational challenges.45
Neutral
Balance Sheet
BioLargo's financial stability is supported by a strong equity position with a debt-to-equity ratio significantly improved over the years, now at 0.17. The equity ratio is healthy at 84.18%. However, the company has high leverage in earlier years and a history of negative net debt, indicating potential liquidity risks.50
Neutral
Cash Flow
Operating cash flow has been consistently negative, reflecting ongoing operational cash burn. Free cash flow growth has not been positive, and the free cash flow to net income ratio remains challenging. While financing activities have supported cash needs, sustained negative cash flows pose a risk to long-term financial health.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 16.29M | 17.78M | 12.23M | 5.88M | 2.53M | 2.43M | Gross Profit |
| 7.10M | 7.85M | 6.15M | 2.86M | 1.10M | 1.23M | EBIT |
| -5.43M | -4.33M | -4.19M | -5.12M | -6.38M | -7.45M | EBITDA |
| -5.13M | -4.06M | -4.19M | -5.10M | -6.70M | -7.83M | Net Income Common Stockholders |
| -3.15M | -2.40M | -3.50M | -4.50M | -7.38M | -10.47M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.56M | 3.55M | 3.54M | 1.85M | 962.00K | 716.00K | Total Assets |
| 10.51M | 10.51M | 8.21M | 4.86M | 3.02M | 4.94M | Total Debt |
| 1.43M | 2.55M | 1.70M | 1.47M | 1.13M | 2.67M | Net Debt |
| -1.14M | -994.00K | -1.84M | -383.00K | 171.00K | 1.96M | Total Liabilities |
| 2.05M | 4.46M | 4.00M | 2.85M | 2.09M | 5.18M | Stockholders Equity |
| 7.61M | 8.85M | 6.84M | 4.88M | 4.65M | 3.86M |
| Cash Flow | Free Cash Flow | ||||
| -5.89M | -4.44M | -2.84M | -3.03M | -3.97M | -4.18M | Operating Cash Flow |
| -5.52M | -3.21M | -2.37M | -2.76M | -3.94M | -4.15M | Investing Cash Flow |
| -454.00K | -1.32M | -478.00K | -271.00K | -34.00K | -123.00K | Financing Cash Flow |
| 4.22M | 4.44M | 4.66M | 3.96M | 4.23M | 4.34M |
BioLargo Technical Analysis
Negative
0.21
Price Trends
0.25
Negative
0.25
Negative
0.24
Negative
Market Momentum
>-0.01
Positive
35.86
Neutral
28.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.25, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.86 is Neutral, neither overbought nor oversold. The STOCH value of 28.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.
BioLargo Risk Analysis
BioLargo disclosed 44 risk factors in its most recent earnings report. BioLargo reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLargo Peers Comparison
Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $430.93M | 3.74 | 11.76% | 2.08% | 7.82% | 19465.71% | |
60 Neutral | $271.10M | ― | -10.12% | ― | 2.20% | 34.71% | |
54 Neutral | $182.22M | 11.43 | -3.29% | 5.77% | -33.92% | -58.53% | |
50 Neutral | $1.98B | -1.08 | -21.29% | 3.61% | 1.96% | -30.59% | |
49 Neutral | $515.36M | ― | -5.28% | ― | -4.23% | -259.01% | |
48 Neutral | $64.17M | ― | -40.03% | ― | 22.97% | 17.32% | |
46 Neutral | $65.98M | ― | -26.63% | ― | -11.91% | -26768.00% |
* Basic Materials Sector Average
Performance Comparison
BLGO
BioLargo
0.21
-0.09
-30.00%
FF
Futurefuel
4.07
-0.49
-10.75%
LXU
Lsb Industries
7.17
-2.66
-27.06%
VHI
Valhi
15.23
-4.11
-21.25%
RYAM
Rayonier Advanced Materials
4.06
-0.95
-18.96%
ORGN
Origin Materials
0.52
-0.43
-45.26%
BioLargo Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q4-2024)
| % Change Since: -12.50%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Positive
BioLargo's earnings call presented a positive outlook, with significant revenue growth and advancements across its subsidiaries. However, challenges in specific projects and revenue fluctuations in key products indicate areas needing attention. Overall, the sentiment is optimistic with caution regarding operational hurdles.Q4-2024 Updates
Positive Updates
Significant Revenue Growth
BioLargo achieved an overall sales and revenue increase of 45%, reaching nearly $18 million. The growth was driven by various subsidiaries, showcasing an accelerated growth path.
Impressive Subsidiary Performance
Odor-No-More saw a revenue increase of 36%, generating $5.9 million in operating income. The engineering division also experienced revenue growth of 183%.
Positive Balance Sheet Developments
BioLargo reported a strong balance sheet, maintaining $3.5 million in cash, increased accounts receivable due to business development, and reduced overall debt.
Pooph Product Success
The Pooph product line, with eight unique products and 15 SKUs, has been performing exceptionally well in retail, contributing significantly to revenue growth.
Clyra Medical Nearing Market Readiness
Clyra Medical is approaching the launch of its innovative product, with significant investments in manufacturing and a successful inspection confirming scale capability.
Negative Updates
Pooph Revenue Fluctuations
Despite its success, Pooph product revenue experienced an ebb and flow, with a noted decrease in Q4 compared to Q3, potentially due to marketing spend adjustments.
Delayed AEC Projects
Projects related to the AEC technology, such as the New Jersey installation, have faced delays due to external factors like weather and construction timelines.
Garratt-Callahan Partnership Challenges
The partnership with Garratt-Callahan for minimum liquid discharge units has not yielded the expected results, with adoption challenges cited.
Battery Technology Validation Delays
Third-party validation for the Spartan cell battery technology has been slower than anticipated, with efforts ongoing to secure necessary validation.
Company Guidance
In the BioLargo Annual 2024 Earnings Results call, the company provided several key metrics that underscore its growth and future potential. The company reported a 45% increase in overall sales and revenue, reaching nearly $18 million. Specific subsidiaries also showed significant growth, with Odor-No-More's revenue increasing by 36%, contributing $5.9 million in operating income. The engineering division saw a 183% increase in third-party revenue, although it still operated at a loss of $1.45 million, down from $1.6 million the previous year. Clyra Medical Technologies, a subsidiary focused on medical products, was identified as the majority contributor to the net loss, which decreased to $4.3 million from $4.6 million. Moreover, the company highlighted substantial investments and partnerships, particularly in the battery and PFAS sectors, indicating a multibillion-dollar opportunity in battery technology and significant cost-saving potential in PFAS treatment. BioLargo also maintained a strong balance sheet with $3.5 million in cash and an increase in accounts receivable, reflecting its expanding business. The company aims to continue its upward trajectory with strategic partnerships and product innovations, setting the stage for potential exits and increased shareholder value.BioLargo Corporate Events
Other
BioLargo Presents at Webcast Investor Conference
Neutral
May 15, 2025
BioLargo, Inc. presented a slide presentation at a webcast investor conference on May 15, 2025. The information shared during this event is not considered filed with the SEC and the company does not have an obligation to update it, although it may choose to do so in the future.
Spark’s Take on BLGO Stock
According to Spark, TipRanks’ AI Analyst, BLGO is a Neutral.
BioLargo’s overall stock score reflects its strong revenue growth and potential future opportunities through strategic partnerships and product innovations. However, challenges in achieving profitability, negative cash flows, and valuation concerns weigh heavily. The technical analysis suggests caution, with potential overbought conditions noted.
To see Spark’s full report on BLGO stock, click here.
Other
BioLargo Presents at Webcast Investor Conference
Neutral
Mar 31, 2025
BioLargo, Inc. presented a slide presentation on March 31, 2025, at a webcast investor conference and plans to release a press statement on April 1, 2025. The company clarified that the information shared is not subject to certain securities liabilities and will not be incorporated into any SEC filings, emphasizing its discretion to update this information as deemed appropriate.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.